TrialCancer2017

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Ahmad A Tarhini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.